|
Giaconda’s focus is the commercialisation of therapies for gastrointestinal diseases and disorders.
The world gastrointestinal pharmaceutical market is estimated to be US$49.9 billion per annum. Giaconda’s products are targeted towards the treatment of serious conditions that are not adequately addressed by any existing therapy. In this way, Giaconda’s products are intended to satisfy these significant unmet medical needs of the gastrointestinal market. Giaconda’s products are primarily underpinned by the scientific rationale that many gastrointestinal conditions are caused by infection. This means that Giaconda’s products have been developed to address the causes of these conditions. Most standard therapies merely manage the symptoms. It is anticipated that Giaconda’s products will enjoy significantly reduced time in development and associated costs as the products are combinations of existing drugs, have shown clinical benefit and address currently unmet needs. Giaconda’s Board and management have a broad range of experience in drug commercialisation, licensing and marketing, combined with medical, financial and commercial expertise. |
|
|
|
